Singapore: Fertile ground for foreign and local medical technology growth
This article was originally published in Clinica
Executive Summary
In a bid to accelerate the growth of a biomedical sciences industry in Singapore, the Singapore Economic Development Board (EDB) set up Bio*One Capital, a dedicated biomedical investment arm. Bio*One Capital's portfolio now encompass over 60 companies worldwide. Swee-Yeok Chu, Bio*One Capital's CEO, gives Clinica Medtech Ventures an insight into the country's fast-growing medtech sector